Pages that link to "Q33939147"
Jump to navigation
Jump to search
The following pages link to Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management (Q33939147):
Displaying 50 items.
- Phosphate binders for preventing and treating bone disease in chronic kidney disease patients (Q24244049) (← links)
- Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease (Q26863412) (← links)
- Artificial receptors for the recognition of phosphorylated molecules (Q27001011) (← links)
- Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider (Q28168531) (← links)
- Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment (Q28213077) (← links)
- Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice (Q28507303) (← links)
- Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients (Q30882562) (← links)
- The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach (Q33616803) (← links)
- Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease (Q33874058) (← links)
- Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study (Q33994155) (← links)
- Optimizing medical management of patients with pre-end-stage renal disease (Q34436559) (← links)
- Compounds in development to combat hyperphosphataemia (Q34481935) (← links)
- The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure (Q34506934) (← links)
- How can the cardiac death rate be reduced in dialysis patients? (Q34549918) (← links)
- Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients (Q34590350) (← links)
- Endocrine abnormalities in chronic renal failure (Q34677226) (← links)
- The role of vitamin D in mild to moderate chronic kidney disease (Q34788496) (← links)
- The roles of the skeleton and phosphorus in the CKD mineral bone disorder (Q35013304) (← links)
- Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review (Q35019709) (← links)
- Nephrology: 4. Strategies for the care of adults with chronic kidney disease. (Q35031111) (← links)
- The role of autophagy in vascular biology (Q35037113) (← links)
- Hyperphosphataemia in renal failure: causes, consequences and current management (Q35091951) (← links)
- Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations (Q35107214) (← links)
- Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells (Q35107539) (← links)
- Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. (Q35249551) (← links)
- Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis (Q35351243) (← links)
- Relationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network (Q35366611) (← links)
- Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment (Q35568749) (← links)
- Catch-up growth with normal parathyroid hormone levels in chronic renal failure (Q35571935) (← links)
- Effects of percutaneous ethanol injection therapy on subsequent surgical parathyroidectomy (Q35573596) (← links)
- The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. (Q35573642) (← links)
- Secondary hyperparathyroidism disease stabilization following calcimimetic therapy (Q35573653) (← links)
- Safety of new phosphate binders for chronic renal failure (Q35593901) (← links)
- Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells (Q35669331) (← links)
- Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly (Q35673804) (← links)
- Calcium agonists in hyperparathyroidism (Q35688223) (← links)
- The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis (Q35826159) (← links)
- Calcimimetics and the treatment of primary and secondary hyperparathyroidism (Q35915930) (← links)
- The therapeutic potential of novel phosphate binders (Q36009640) (← links)
- Medical and surgical treatment for secondary and tertiary hyperparathyroidism (Q36013623) (← links)
- Paricalcitol: a review of its use in the management of secondary hyperparathyroidism (Q36055471) (← links)
- Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis (Q36061887) (← links)
- Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. (Q36066111) (← links)
- Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial (Q36138126) (← links)
- Nocturnal eating disturbs phosphorus excretion in young subjects: a randomized crossover trial (Q36142210) (← links)
- Hemodialysis in children: general practical guidelines (Q36158150) (← links)
- Minimizing bone abnormalities in children with renal failure (Q36561062) (← links)
- The safety of phosphate binders. (Q36565049) (← links)
- Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies (Q36567144) (← links)
- The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism (Q36666922) (← links)